Ticagrelor

Ticagrelor

File:Ticagrelor3.png
File:Ticagrelor ball-and-stick animation.gif
Clinical data
Trade names	Brilinta, Brilique, Possia
Synonyms	AZD-6140
MedlinePlus	a611050
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Ticagrelor
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	B01AC24 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	36%
Protein binding	>99.7%
Metabolism	Hepatic (CYP3A4)
Elimination half-life	7 hrs (ticagrelor), 8.5 hrs (active metabolite AR-C124910XX)
Excretion	Biliary
Identifiers
IUPAC name (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
CAS Number	274693-27-5 Y
PubChem CID	9871419
ChemSpider	8047109 N
UNII	GLH0314RVC
KEGG	D09017 Y
ChEMBL	ChEMBL398435 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H28F2N6O4S
Molar mass	522.567 g/mol
3D model (JSmol)	Interactive image
SMILES CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
InChI InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1 N Key:OEKWJQXRCDYSHL-FNOIDJSQSA-N N
NY (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2] Synonyms / Brand Names: Lopressor, Toprol XL

Overview

Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.

Category

P2Y12 platelet inhibitor, platelet aggregation inhibitor